What are the top BPC-157 studies — the published papers that shaped what researchers know about this peptide? BPC-157 (Body Protection Compound 157) is a synthetic fifteen-amino-acid peptide derived from a protein found in human gastric juice, and its research record is unusual: one Croatian research group has produced the large majority of the published work, spanning tendons, ligaments, and muscle. This guide walks through the top BPC-157 studies one by one — each paper’s design, measurements, and reported results. Everything below is strictly research framing: animal and cell studies plus registered human trials with no posted results. Nothing here is medical advice or a suggestion about human use.
Research-use-only disclaimer: BPC-157 is not an FDA-approved drug. It is handled as a research compound for laboratory investigation only. This article summarizes the top BPC-157 studies as published research — no dosage information, no usage instructions, no medical advice.
BPC-157 in brief: BPC-157 is a synthetic pentadecapeptide derived from a protein found in human gastric juice. The most-cited studies are the Sikirić group’s rat tendon, muscle and ligament papers from 2003 to 2010, plus the 2019 Gwyer review and the registered PCO-02 Phase 1 trial. BPC-157 is supplied in the Wolverine Blend with TB-500 and in the GLOW Blend with GHK-Cu and TB-500, each with a lot-specific Certificate of Analysis. BPC-157 is for laboratory research use only.
How the Top BPC-157 Studies Were Selected
Compiling the top BPC-157 studies requires ground rules: nearly all influential work comes from the group led by Predrag Sikirić at the University of Zagreb’s medical school — deep in some tissues, narrow in authorship.
Selection criteria: indexed in PubMed or a major publisher’s catalog; original experimental data; a defined tissue or model with stated methods and measured outcomes; cited by later reviews as a key reference. One registered human trial is included as the earliest human clinical entry.
Top BPC-157 Studies at a Glance
Six entries made the cut — the top BPC-157 studies by the criteria above: five original experimental studies and one registered human trial, spanning 2003 to the present registry record.
| # | Study | Model | Tissue focus | Why it matters |
|---|---|---|---|---|
| 1 | Staresinić et al., 2003 | Rat Achilles tendon transection + tendocyte culture | Tendon | First major tendon-healing paper; combined in vivo and in vitro work |
| 2 | Pevec et al., 2010 | Rat muscle crush injury, with and without corticosteroid | Muscle | Tested BPC-157 against corticosteroid-impaired healing |
| 3 | Cerovecki et al., 2010 | Rat medial collateral ligament transection | Ligament | 90-day ligament study across three administration formats |
| 4 | Myotendinous junction study (Japjec et al.) | Rat quadriceps tendon–muscle separation | Muscle–tendon junction | A defect that does not heal on its own — tested to disappearance |
| 5 | Gwyer, Wragg & Wilson, 2019 | Literature review | Musculoskeletal overview | The most-cited synthesis of the musculoskeletal evidence |
| 6 | PCO-02 (NCT02637284) | Registered Phase 1 trial | Human safety/PK | The first registered human trial of BPC-157 itself |

Study 1: Staresinić et al., 2003 — Transected Rat Achilles Tendon
Paper: “Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth” — Staresinić and colleagues, 2003.
Model: The right Achilles tendon of rats was surgically transected 5 mm above its calcaneal insertion, leaving a large defect between the cut ends — a severe injury model in which control animals heal poorly, and the template for later top BPC-157 studies.
How the peptide was handled: Dissolved in saline with no carrier added, given once daily beginning 30 minutes after surgery, with the last application 24 hours before each assessment. Control animals received saline.
What was measured: Daily Achilles functional index plus biomechanical (load of failure, Young’s modulus), microscopic (inflammatory cells; fibroblast and collagen formation), and macroscopic assessments on days 1–14.
What the authors reported: Controls healed poorly. The BPC-157 groups reportedly improved across all four assessment types — higher load of failure and Young’s modulus, higher functional index values, more favorable cell profiles with superior fibroblast and collagen formation, and smaller defects progressing to full tendon integrity.
The in vitro half: In cultured tendocytes, BPC-157 alone did not change cell growth, but it consistently reversed the growth-inhibiting effect of 4-hydroxynonenal (HNE) into growth stimulation — in both treatment orders, with or without serum.
Historical note: The paper described BPC-157 (also coded PL 14736) as then being in clinical trials for inflammatory bowel disease under the code PLD-116 — the program’s status at publication, not a claim about today.
This paper is first on any list of the top BPC-157 studies because it set the template the later musculoskeletal work followed: a defined surgical defect, daily functional scoring, biomechanics plus histology, and a parallel cell-culture experiment probing mechanism. Every subsequent entry in the top BPC-157 studies list follows the template it established.
Study 2: Pevec et al., 2010 — Muscle Healing Under Corticosteroid Impairment
Paper: “Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application” — Pevec and colleagues, 2010 (PMID: 20190676).
Model: Rats with gastrocnemius muscle complex injury — transection and crush models — some groups additionally receiving systemic 6-alpha-methylprednisolone, a corticosteroid known to impair healing.
How the peptide was handled: Without a carrier, either systemically or as a topical cream, across the tested dose ranges — once right after injury or once daily, assessed on days 1, 2, 4, 7, and 14 (functional, macroscopic, and histological measures).
What the authors reported: Untreated crushed-muscle controls showed limited improvement; the corticosteroid markedly aggravated healing. BPC-157 reportedly induced faster healing and full functional restoration even under systemic corticosteroid treatment, systemically or locally. The paper’s conclusion: BPC-157 completely reversed corticosteroid-impaired muscle healing in this model, with a counteracting effect in tendon-to-bone healing as well.
This study earns its place among the top BPC-157 studies because it tested the peptide under deliberately worsened conditions — a stricter test than healing an ordinary defect. As with every entry here, the findings describe rats, not people.

Study 3: Cerovecki et al., 2010 — Medial Collateral Ligament Healing Over 90 Days
Paper: “Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat” — Cerovecki and colleagues, Journal of Orthopaedic Research, 2010 (PMID: 20225319).
Model: Surgical transection of the medial collateral ligament (MCL) in rats, followed for a full 90 days — the longest observation window among the landmark musculoskeletal papers.
How the peptide was handled: Three formats side by side — systemic, per-oral in drinking water, and topical as a thin cream at the injury site — first application 30 minutes after surgery in every group.
What was measured: Functional, biomechanical, macroscopic, and histological healing across the 90-day period.
What the authors reported: Consistent healing improvements across all formats and assessment types. Referencing earlier findings on early growth response 1 (egr-1) gene expression in wound healing, the authors concluded BPC-157 improved acute ligament-injury healing and warranted further ligament-therapy investigation.
Among the top BPC-157 studies, this one stands out for breadth of administration: systemic, oral, and local formats all tested in the same injury model — a design that speaks to the peptide’s reported stability in gastric conditions.
Study 4: The Myotendinous Junction Study — A Defect That Does Not Heal Alone
Paper: A study by Japjec and colleagues on pentadecapeptide BPC-157 and the healing of the dissected quadriceps tendon from the quadriceps muscle in rats.
Model: The quadriceps tendon surgically separated from the quadriceps muscle — a myotendinous junction defect the authors documented as unable to heal spontaneously in rats.
How the peptide was handled: Systemically and per-orally in drinking water at the tested dose levels, beginning right after surgery; assessed at 7, 14, 28, and 42 days (macro- and microscopic, biomechanical, functional, plus eNOS/COX-2 mRNA and oxidative-stress/nitric-oxide markers).
What the authors reported: Prominent treatment effects across assessment types, with eNOS, COX-2, oxidative-stress, and nitric-oxide markers counteracted toward normal, and the progressive muscle atrophy of controls counteracted. Defects shrank and, by days 28–42, disappeared in treated rats — well-oriented recovered tissue, no remaining inflammatory infiltrate.
This entry belongs on any serious list of the top BPC-157 studies because of the model’s severity: choosing a defect that cannot heal on its own makes any recovery in the treated group unambiguous. The nitric-oxide-pathway readouts also make it one of the more mechanism-oriented papers in the series.

Study 5: Gwyer, Wragg & Wilson, 2019 — The Musculoskeletal Review
Paper: “Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing” — Gwyer, Wragg, and Wilson, Cell and Tissue Research, 2019.
What it is: A peer-reviewed literature review — not a new experiment — surveying the musculoskeletal BPC-157 literature: tendon, ligament, skeletal muscle, and bone studies from the Sikirić group.
Background it established: The review traces BPC-157 to its first publication by Sikirić and colleagues in 1993 in the Journal of Physiology (Paris) — a 15-amino-acid fragment (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a human gastric juice protein, also appearing as bepecin, PL 14736, PL-10, and PLD-116.
Reviews generate no new data, but this one matters for the top BPC-157 studies conversation as the paper other researchers cite as the single entry point into the musculoskeletal evidence.
Study 6: PCO-02 (NCT02637284) — The First Registered Human Trial
Record: “PCO-02 – Safety and Pharmacokinetics Trial,” registered on ClinicalTrials.gov (NIH).
Design: A Phase 1 trial in healthy volunteers, sponsored by PharmaCotherapia d.o.o., studying the safety and pharmacokinetics of BPC-157, described in the registry as a pentadecapeptide from a gastric source — the only human entry among the top BPC-157 studies.
Registry facts: Estimated enrollment of 42 participants; study start listed as October 2015; overall status shown as unknown.
What it tells us: Very little beyond its existence — no results are posted. For the top BPC-157 studies list, its importance is as a marker: the earliest registered clinical trial of BPC-157 itself in humans. (A 2025 literature review identified only limited clinical evidence beyond the registry record, including a small retrospective study of 12 patients with knee pain.)
Including a resultless trial among the top BPC-157 studies is the honest way to show where the human evidence stands: one small Phase 1 safety and pharmacokinetics study, registered a decade ago, status unknown, no posted results. Newer BPC-157-related registrations (hamstring strain, rotator cuff recovery, a peptide gummy) are tracked on ClinicalTrials.gov.
What the Top BPC-157 Studies Have in Common
Reading the top BPC-157 studies back to back, several patterns shape how seriously a researcher can take the literature.
Pattern 1 — One group, one playbook. The landmark studies share authorship and a consistent template: defined surgical defect, saline controls, daily functional scoring, biomechanics plus histology. Consistency aids comparability — and limits independent replication.
Pattern 2 — Effects reported across formats. The ligament study tested systemic, oral, and topical formats side by side and reported improvements with all three — consistent with the compound’s reported gastric stability.
Pattern 3 — Severe models, strong contrasts. Several studies chose models where controls heal badly — the large Achilles defect, corticosteroid-impaired muscle, the non-healing junction. That makes effects easier to detect but says little about milder injuries.

Where the Evidence Still Falls Short
An honest list of the top BPC-157 studies has to include the gaps, because they are large.
The species gap: apart from the single small registered Phase 1 trial, every landmark study here used rats or cell culture — and rodent tendon, ligament, and muscle biology differs from human biology in ways that matter for healing.
The independence gap: the experimental core of this literature comes overwhelmingly from one research group. Independent replication by unaffiliated laboratories is how findings earn trust, and this literature has comparatively little of it.
The mechanism gap: beyond the nitric-oxide-pathway readouts in the junction study, the literature reports what happened far more than it explains how.
The regulatory gap: BPC-157 is not an FDA-approved drug, and its compounding status was on the agenda at FDA’s July 2026 Pharmacy Compounding Advisory Committee meeting — research interest and regulatory standing are two different things.
None of this erases the studies. It frames them: concentrated animal research with striking reported effects in severe models, awaiting the independent replication and human data that would move it from interesting to established.
Key Takeaways: Top BPC-157 Studies
- The landmark literature is dominated by the Sikirić group’s rat studies: tendon (Staresinić 2003), muscle under corticosteroid impairment (Pevec 2010), ligament over 90 days (Cerovecki 2010), and the myotendinous junction.
- Consistent template across studies — defined surgical defects, saline controls, daily functional scoring, biomechanics plus histology — with reported improvements across all assessment types in severe models.
- Mechanistic work is thin: the nitric-oxide-pathway readouts in the junction study are among the few attempts to explain how rather than what.
- The Gwyer 2019 review remains the standard single entry point into the musculoskeletal evidence.
- Human data is essentially absent: the small registered Phase 1 safety trial (PCO-02) with no posted results is the earliest registered record.
- Research framing only: animal findings establish nothing about human use, and BPC-157 is not an FDA-approved drug.
Top BPC-157 Studies: Frequently Asked Questions
Quick answers on the top BPC-157 studies, in research framing.
What is the most-cited BPC-157 study?
The 2003 Staresinić paper on transected rat Achilles tendon is the foundational musculoskeletal study. The 2019 Gwyer review is the most-cited synthesis, treating Staresinić 2003 as the starting point of the tendon literature.
Were the top BPC-157 studies done in humans or animals?
Animals. Every landmark experimental entry in the top BPC-157 studies used rats or cell culture. The earliest human entry is the registered PCO-02 Phase 1 safety and pharmacokinetics trial (NCT02637284), which has no posted results; a 2025 review found only limited additional clinical evidence. None of the top BPC-157 studies establish anything about effects in people.
Who conducted most of the BPC-157 research?
The group led by Predrag Sikirić at the University of Zagreb’s medical school in Croatia — consistent methods across studies, but limited independent replication so far.
What tissues do the top BPC-157 studies cover?
Tendon (Achilles transection, tendocyte culture), ligament (medial collateral ligament over 90 days), skeletal muscle (including under corticosteroid impairment), the myotendinous junction, and bone in the earlier literature.
Is BPC-157 FDA-approved based on these studies?
No. Animal studies do not constitute the basis for drug approval, and BPC-157 is not an FDA-approved drug. The top BPC-157 studies are preclinical research; regulatory standing is a separate matter.
Where can researchers find the original papers?
The ligament and muscle papers are indexed on PubMed (PMIDs 20225319 and 20190676), the 2019 review appeared in Cell and Tissue Research, and the registered trial is listed on ClinicalTrials.gov as NCT02637284.
Final Notes on the Top BPC-157 Studies
The top BPC-157 studies tell a coherent story: a stable gastric-derived pentadecapeptide, tested in severe rat models of tendon, ligament, and muscle injury, reported to improve healing across functional, biomechanical, and histological measures — holding under corticosteroid impairment and across systemic, oral, and local formats. The limits are equally clear: one dominant research group, almost no independent replication, thin mechanistic explanation, essentially no human data.
That is what the landmark literature supports: concentrated preclinical work with striking reported effects and major unanswered questions. For researchers working through the top BPC-157 studies, the methods sections — defined defects, daily scoring — are where the literature’s real content lives. For tracking where the field goes next, the registry record is the place to watch.
Research-use-only reminder: All products on this site, including the KLOW Blend that also supplies BPC-157 with KPV, GHK-Cu and TB-500, are sold strictly for laboratory research use, with a lot-specific Certificate of Analysis. This article is educational, contains no medical advice, and recommends no human use of any compound. For the peptide BPC-157 is most often paired with, Top TB-500 Studies lists the most influential thymosin beta-4 papers.


2 Comments